里程碑制药公司获CARDAMYST关键专利保护
蒙特利尔和北卡罗来纳州夏洛特讯 - 市值1.46亿美元、专注于创新心血管治疗的里程碑制药公司（NASDAQ:MIST）已从美国专利商标局（USPTO）获得一项与其主要研究产品etripamil鼻喷剂（商品名CARDAMYST™）相关的新专利授权通知。该公司股票表现强劲，过去六个月涨幅超过62%。根据 InvestingPro ...
来自MSN1 个月
H.C. Wainwright maintains $25 target on Milestone shares
H.C. Wainwright estimates that CARDAMYST could generate revenues exceeding $1 billion, considering its application in both PSVT and AFib-RVR if approved. The firm believes that the market has yet ...
Taiwan News13 天
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...
Nasdaq1 个月
Milestone Pharmaceuticals Announces PDUFA Date for CARDAMYST™ Nasal Spray and Plans for ...
It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid ...
Nasdaq1 个月
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on ...
It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid ...
Milestone wins Buy at Rodman & Renshaw on potential Cardamyst approval
Based on the Phase 3 data generated from MIST’s RAPID trial in PSVT, Rodman & Renshaw analyst ... enrollments in 2025 for ...